Original Query: miksad
Previous Study | Return to List | Next Study

Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00813293
Recruitment Status : Active, not recruiting
First Posted : December 23, 2008
Last Update Posted : February 27, 2017
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Onyx Therapeutics, Inc.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Rebecca Miksad, MD, MPH, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Primary Completion Date : December 2016
  Estimated Study Completion Date : December 2017